Replune FDA Panel Votes Favorably on RP1

RP1's IGNYTE study efficacy results were deemed evaluable and clinically meaningful by the FDA's Cell, Tissue, and Gene Therapies Advisory Committee. The favorable outcome is a key regulatory milestone as the company awaits an August 2 action date.